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Abstract
In 2016, the World Health Organization (WHO) recommended point-of-use fortification of complementary foods
with iron-containing micronutrient powders to improve iron status and reduce anaemia in children at risk of
anaemia. This recommendation continues to be debated. In a recent trial among Kenyan children aged 12–36
months, we found no evidence that daily point-of-use fortification was efficacious in improving haemoglobin
concentration or plasma iron markers. An updated meta-analysis indicated that, on average, in an arbitrarily
selected setting and with adherence as obtained under trial conditions, one may expect a small increase in
haemoglobin concentration in preschool children, with the upper limit of the 95% CI virtually excluding an effect
beyond 5.5 g/L. In the present paper, we elaborate on the interpretation of these findings and the meta-analyses
that formed the basis for the WHO guidelines. In particular, we draw attention to the phenomenon that small
group differences in the distribution of continuous outcomes (haemoglobin concentration, ferritin concentrations)
can give a false impression of relatively large effects on the prevalence of the dichotomised outcomes (anaemia,
iron deficiency).
Please see related articles: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0839-z, https://
bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0867-8
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Background
Point-of-use fortification of foods is recommended by
the World Health Organization (WHO) [1] as an alter-
native to mitigate or overcome the constraints associated
with supplementation and industrial food fortification.
In this new approach, powders containing a mixture of
vitamins and minerals are supplied as small, single-
serving packets, the contents of which can be mixed into
semi-solid food prior to consumption.
In a recent placebo-controlled trial among Kenyan chil-
dren aged 12–36 months, we found no evidence that daily
point-of-use fortification with either 3 mg iron as
NaFeEDTA or 12.5 mg iron as ferrous fumarate was effi-
cacious in improving haemoglobin concentration or
plasma iron markers [2]. As discussed in a commentary
[3], the decline in anaemia prevalence over time that we
observed in all intervention groups may have been due to
premedication with anti-malarial and anti-helminth medi-
cation at baseline, or due to the vitamin A or zinc content
in the fortification powders. However, attribution of such
time trends is impossible since the observed effects may
also have been due to various other factors, including sea-
sonal variation in nutrient status or infections, age
changes or regression to the mean. Thus, these temporal
changes in anaemia prevalence cannot be per se inter-
preted as evidence to support the use of micronutrient
powders in an effective intervention strategy. Reviews of
the impact of multi-micronutrient powders on indicators
other than iron deficiency or anaemia have been inconclu-
sive [4, 5], and unfortunately there is little evidence from
randomised trials to show that point-of-use fortification
leads to improved vitamin A or zinc status [6].
Summary measures of intervention effect
The effect of an intervention for any person is best de-
fined as the difference between the outcomes as a result
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of receiving the intervention and those that would have
resulted had the intervention been denied [7]. Under
such a counterfactual view of causality, an effect can be
operationally estimated as the difference in endpoints
between groups concurrently randomised to verum (i.e.
to the active substance under investigation) or control.
In our trial, compared to placebo, point-of-care fortifica-
tion with NaFeEDTA at the end of intervention led to a
reduction in the prevalence of iron deficiency by 20.1%
(from 44.6% to 24.5%). However, effects on iron defi-
ciency should be interpreted with caution since a small
group difference in the distribution of a continuous out-
come can misleadingly result in a relatively large differ-
ence in prevalence of the dichotomised outcome,
whether expressed as a relative or absolute difference.
Thus, point-of-use fortification with NaFeEDTA im-
proved geometric mean plasma ferritin concentrations
by only 4 μg/L (from 29.7 to 33.7 μg/L), which may
seem much less impressive than suggested by the ob-
served 20.1% decrease in prevalence of iron deficiency,
an outcome variable that was derived by dichotomising
plasma ferritin concentration.
Similar issues arise in the interpretation of effect esti-
mates of the meta-analyses that formed the basis of the
WHO guidelines, which showed absolute effects on
haemoglobin and ferritin concentrations that may seem
much less impressive than the corresponding relative re-
ductions in anaemia and iron deficiency [1]. For example,
in the WHO meta-analysis, in children aged 2–12 years,
point-of-care fortification with multiple micronutrient
powders increased haemoglobin concentration by 3.4 g/L
(95% CI 0.9–5.8 g/L) as compared to a reduction in an-
aemia risk by 34% (95% CI 12–51%) [1]. In trials and
meta-analyses, priority should be given to effects on con-
tinuous outcomes. Relative effects on dichotomised out-
comes can be useful to allow extrapolation of trial results
over time and in different settings, but they should be
given secondary importance, and extrapolated results
should be re-converted to the continuous outcome to
appreciate the true public health gains.
Future directions and conclusions
Our meta-analysis suggested a small gain in haemoglo-
bin concentration in most trials, indicating that point-
of-use fortification with iron-containing micronutrient
powders provides some benefit across different settings
[2]. On average, in an arbitrarily selected setting, and
with an adherence as obtained under trial conditions,
one may expect an increase in haemoglobin concentra-
tion by only 3.9 g/L, with the upper limit of the 95% CI
virtually excluding an effect beyond 5.5 g/L; the attenu-
ated effect that is likely to be achieved under real-world
conditions is even lower.
The recently published Global Burden of Disease esti-
mates [8] have confirmed that iron deficiency anaemia is
by far the most prevalent micronutrient issue worldwide
and remains a scourge of humanity. The motive behind
our robust interpretation of the low efficacy of multiple
micronutrient powders is to encourage researchers, re-
search funders and policymakers to continue to investi-
gate the underlying reasons for the low efficacy. For
instance, we have strong evidence that hepcidin blocks
iron absorption in young children in response to even
very low levels of inflammation (Prentice et al., submit-
ted). Alleviation of such inflammation, regardless of the
means, would likely improve the efficacy of all methods
used to increase the iron content in children’s diets.
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